Premium
Cell‐Based Biological Evaluation of a New Bisamide FMS Kinase Inhibitor Possessing Pyrrolo[3,2‐ c ]pyridine Scaffold
Author(s) -
ElGamal Mohammed I.,
AbdelMaksoud Mohammed S.,
ElDin Mahmoud M. Gamal,
Yoo Kyung Ho,
Baek Daejin,
Oh ChangHyun
Publication year - 2014
Publication title -
archiv der pharmazie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 61
eISSN - 1521-4184
pISSN - 0365-6233
DOI - 10.1002/ardp.201400051
Subject(s) - kinase , chemistry , selectivity , pyridine , cell culture , ic50 , potency , cell growth , lead compound , stereochemistry , growth inhibition , biological activity , structure–activity relationship , biochemistry , biology , in vitro , medicinal chemistry , genetics , catalysis
A bisamide compound 1 possessing the pyrrolo[3,2‐ c ]pyridine nucleus was synthesized and biologically evaluated. It was tested for kinase inhibitory activity over a panel of 47 kinases, and its selectivity toward the FMS kinase was accidentally discovered. Compound 1 was tested over a panel of seven ovarian, two prostate, and six breast cancer cell lines at a single dose concentration of 10 µM and showed high activity. It was further tested in a 5‐dose mode to determine its IC 50 and total growth inhibition (TGI) values over the 15 cell lines. Compound 1 showed high potency on the submicromolar scale and good efficacy. The cytotoxic effect of compound 1 over peritoneal macrophages was also investigated. Compound 1 demonstrated higher selectivity against different cancer cell lines compared with HS‐27 fibroblasts.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom